CMMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chemomab Therapeutics Ltd (CMMB) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows no strong positive catalysts, weak financial performance, and lacks trading signals or significant trading trends. Additionally, the technical indicators and stock trend analysis do not suggest a compelling entry point.
The MACD is slightly positive at 0.0511 but contracting, indicating weakening momentum. The RSI is neutral at 58.426, and moving averages are converging, showing no clear trend. Support and resistance levels are at S1: 1.434 and R1: 1.93, with the current price at 1.85 near resistance, suggesting limited upside potential.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock price dropped 4.19% in the regular market and 0.52% in pre-market trading. Financial performance is weak, with net income and EPS showing significant declines. Stock trend analysis predicts a 19.25% chance of decline over the next month.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped by 49.99% YoY to -1,742,000, and EPS fell by 100%. Gross margin also remained at 0, indicating no profitability.
No analyst rating or price target changes were provided.
